Less than a week after inking a deal with with six health systems, Verily — the life sciences arm of Google parent company Alphabet — kicked off another round of partnerships aimed at clinical research with pharma companies Novartis, Sanofi, Otsuka, and Pfizer, per CNBC.

Why this matters: The aim of the new partnerships is to make it easier for patients to enroll in clinical trials and to utilize tech like electronic health records (EHRs) and wearables to aggregate data.

Behind the numbers: The number of patients who participate in clinical trials is meager: Only about 3% of adult cancer patients take part in clinical trials, and difficulties recruiting patients could contribute to the cost of developing an oncology treatment, which costs drug developers up to $2 billion over an average of seven years.